Charting
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Oversold MMJ charts on watch for bounces
AEGY pincher overold on daily
LATF boune off 200ma
AVOP down on very low volume .. keep on radar for news and run
DBMM MMJ rumor lotto
wow BMSN huge FDA news
Regen BioPharma, a Majority Owned Subsidiary of Bio-Matrix Scientific Group, Provides Update on HemaXellerate I(TM) IND for T...
Date : 05/12/2014 @ 12:30PM
Source : Marketwired
Stock : Bio-matrix Scientific Group, Inc. (PC) (BMSN)
Quote : 0.0042 0.0018 (75.00%) @ 1:00PM
Regen BioPharma, a Majority Owned Subsidiary of Bio-Matrix Scientific Group, Provides Update on HemaXellerate I(TM) IND for T...
Print
Alert
Bio-matrix Scientific Group, Inc. (PC) (USOTC:BMSN)
Intraday Stock Chart
Today : Monday 12 May 2014
Click Here for more Bio-matrix Scientific Group, Inc. (PC) Charts.
Regen BioPharma, a Majority Owned Subsidiary of Bio-Matrix Scientific Group, Provides Update on HemaXellerate I(TM) IND for Treatment of Drug Resistant Aplastic Anemia
Company Passes Manufacturing and Clinical Reviewers, Clarification of Safety Studies Requested by FDA
SAN DIEGO, CA--(Marketwired - May 12, 2014) - Regen BioPharma Inc., a majority owned subsidiary of Bio-Matrix Scientific Group Inc. (PINKSHEETS: BMSN), announced today an update on its IND # 15376 for use of HemaXellerate I™ in treatment of patients with drug refractory aplastic anemia.
On March 6, 2014, Regen submitted a protocol modification, additional details on manufacturing, and new data to the FDA regarding therapeutic effects of HemaXellerate I™ in animal models of diseases similar to aplastic anemia in humans, as well as additional safety data.
The Company reports the FDA accepted the clinical protocol and the product manufacturing information provided, however, clarification on animal safety studies was requested.
"Given the HemaXellerate I™ product is derived from the patient's own fat tissue, and numerous key opinion leaders support clinical entry of our product, as demonstrated by our peer reviewed publication http://www.translational-medicine.com/content/pdf/1479-5876-10-231.pdf., we are confident the safety studies the FDA requested clarification on can be addressed in a timely fashion," stated Thomas Ichim, Regen's Chief Scientific Officer and Board Member.
"The role of the FDA is to ensure the highest standards of safety for new products. We view the requested clarifications from the FDA in regards to safety studies as part of the normal process of FDA submission. Given that the HemaXellerate I™ possesses the potential to treat multiple conditions, we view the demonstration of safety as a fundamental step, which will position the Company to expand use of this 'stem cell drug' for multiple other indications," noted David Koos, the Company's Chairman & CEO. "Having passed the clinical trial protocol approval and the manufacturing approval, are major milestones for Regen."
On May 9, 2014 the Company updated its IND with changes requested by the FDA and submitted them for review.
About Regen BioPharma: Regen BioPharma, Inc., a majority owned subsidiary of Bio-Matrix Scientific Group, Inc. (PINKSHEETS: BMSN), is a biotechnology company focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is focused on developing treatments for Aplastic Anemia and a gene silencing therapy for treating cancer. For more information refer to the company's website http://www.regenbiopharma.com/
wow BMSN huge FDA news
Regen BioPharma, a Majority Owned Subsidiary of Bio-Matrix Scientific Group, Provides Update on HemaXellerate I(TM) IND for T...
Date : 05/12/2014 @ 12:30PM
Source : Marketwired
Stock : Bio-matrix Scientific Group, Inc. (PC) (BMSN)
Quote : 0.0042 0.0018 (75.00%) @ 1:00PM
Regen BioPharma, a Majority Owned Subsidiary of Bio-Matrix Scientific Group, Provides Update on HemaXellerate I(TM) IND for T...
Print
Alert
Bio-matrix Scientific Group, Inc. (PC) (USOTC:BMSN)
Intraday Stock Chart
Today : Monday 12 May 2014
Click Here for more Bio-matrix Scientific Group, Inc. (PC) Charts.
Regen BioPharma, a Majority Owned Subsidiary of Bio-Matrix Scientific Group, Provides Update on HemaXellerate I(TM) IND for Treatment of Drug Resistant Aplastic Anemia
Company Passes Manufacturing and Clinical Reviewers, Clarification of Safety Studies Requested by FDA
SAN DIEGO, CA--(Marketwired - May 12, 2014) - Regen BioPharma Inc., a majority owned subsidiary of Bio-Matrix Scientific Group Inc. (PINKSHEETS: BMSN), announced today an update on its IND # 15376 for use of HemaXellerate I™ in treatment of patients with drug refractory aplastic anemia.
On March 6, 2014, Regen submitted a protocol modification, additional details on manufacturing, and new data to the FDA regarding therapeutic effects of HemaXellerate I™ in animal models of diseases similar to aplastic anemia in humans, as well as additional safety data.
The Company reports the FDA accepted the clinical protocol and the product manufacturing information provided, however, clarification on animal safety studies was requested.
"Given the HemaXellerate I™ product is derived from the patient's own fat tissue, and numerous key opinion leaders support clinical entry of our product, as demonstrated by our peer reviewed publication http://www.translational-medicine.com/content/pdf/1479-5876-10-231.pdf., we are confident the safety studies the FDA requested clarification on can be addressed in a timely fashion," stated Thomas Ichim, Regen's Chief Scientific Officer and Board Member.
"The role of the FDA is to ensure the highest standards of safety for new products. We view the requested clarifications from the FDA in regards to safety studies as part of the normal process of FDA submission. Given that the HemaXellerate I™ possesses the potential to treat multiple conditions, we view the demonstration of safety as a fundamental step, which will position the Company to expand use of this 'stem cell drug' for multiple other indications," noted David Koos, the Company's Chairman & CEO. "Having passed the clinical trial protocol approval and the manufacturing approval, are major milestones for Regen."
On May 9, 2014 the Company updated its IND with changes requested by the FDA and submitted them for review.
About Regen BioPharma: Regen BioPharma, Inc., a majority owned subsidiary of Bio-Matrix Scientific Group, Inc. (PINKSHEETS: BMSN), is a biotechnology company focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is focused on developing treatments for Aplastic Anemia and a gene silencing therapy for treating cancer. For more information refer to the company's website http://www.regenbiopharma.com/
Tec
With this shareholder update things look very good here. You will always have short term spikes and falls the pps of penny stocks. However with ANAS they appear to be building a real deal MMJ and alternative medicine company. I feel those going long here will reap very big rewards.
2885 Sanford Ave SW Suite:
28452
Grandville, MI 49418
Phone: 616
-
244
-
8500
*
Email: Info@alternaturals.com
*
Web: www.alternaturals.com
Dear Shareholders,
I am writing you to answer several questions I have
received from shareholders
, to calm so
me of
the concerns that some of you apparently have, and quell some rumors that have been
perpetuated throughout various Internet sites. I am going to try to do this while navigating a maze
of guidelines set down by our legal counsel in order to protect bo
th you and the company, and
keep the integrity of our non
-
disclosure agreements in tact, so please forgive the fact that I may
have to use generality in some cases and not specifics.
First, to address the press releases that have come out since the name c
hange took effect. There
are certain requirements of disclosure we must make and this was exactly what these releases
were.
They in no way represent the quality of news the company has, or that the company has no
real news
at all
,
and they were not simply
“filler” or attempts at increasing awareness. We had to
get them out of the way for many reasons and as originally stated we needed to wait a week or so
to announce real news about our business.
As I prepare to begin announcing our actual business advance
ments and show the world that we
will be a driving force in many industries, I must ask for cooperation from all of you. I know the
temptation to do your own checking and “investigations” is great, but we have to ask that you
refrain from calling on, email
ing, or visiting partners and clients as we announce them to verify
our information. This will cause us to have a real need for secrecy and we will not be able to
announce the names of our partners if they are to be hounded by calls and emails. Everyone
in
volved should know very well from history that if a press release about a partnership with a
fortune 500 company is not what it seems, it does not take them very long to litigate and force the
release to be retracted. In the past year alone, several compan
ies have actually had their
securities halted within a day of putting out false news. If we put out news about our relationship
with a successful company, and are not forced to retract it within a day, you can be 100% sure
that it was accurate. Again, ple
ase refrain from individual checking as it will damage our
relationships
and cause us to have the need to
suppress
informatio
n
.
You are all yet unaware of the level of business we have
in place
, and of the size of our partners
and supporters, and I assure you that as it comes out you will not only
be pleased, but amazed
and surprised. I feel we have agreements in place that
will really take the world by surprise, and
when we announce them, it will cause pretty big excitement throughout healthcare, nutritional,
and retail industries, possibly to the
point of being front
-
page news, which will be very exciting.
We plan to make a very big splash.
Another iss
ue everyone seems to be fixated on is that of the “buyback” program announced
recently. We were advised to make our PR disclosure narrow in scope a
nd we did, but I can tell
you that we have the money and means to trim our outstanding shares down by 1/3 or more. This
will take as long (or short) a period as the market allows, and I plan to be aggressive. Will this
help the stock price? I don’t know. T
his market is based mostly on speculation and until we move
up to the OTCQB and then the QX,
as is planned for later this
year;
the share price may not
reflect the company’s true value.
The one point that I want to drive home is that we do not benefit in any way by anyone selling
stock. We
are not interested in selling stock, and nothing we say or do is aimed at making it
easier for anyone to sell stock. We are focused on our business and while the shares price is of
great interest to me, it does not effect any of us financially, so there s
hould be no worry of
“dumping”, or “Selling” by
us, or
by anyone we know.
Our benefactors, specifically Eastlight Enterprises (Ray Barton), and others are of the same
beliefs and I assure you they are focused on growth and not of the type mostly associate
d with
“penny stocks”. I’ve been asked about Barton and his associates several times now, and again I
assure everyone that whatever you have heard, if it is negative, it is completely untrue. I did
extensive due diligence and these people are 100% on the l
evel, and true to their word.
None of
them have ever been in any type of trouble, and none of them have done anything but go above
and beyond the call of duty for every one of the companies they invest in or consult for. I checked
many references.
With al
l of that out of the way, I want to tell you all that I truly believe that Alternaturals is the most
exciting project
you will
ha
ve seen in many many years. W
e have planned for this for a very long
time
,
so we really do not plan to stagnate. Lastly, I want to
thank each and every one of you for
taking an interest in Alternaturals, and I hope you watch our progress for a long time so you can
see the American
dream
taking
place
first hand.
Thank you all,
Emmanuel Gyamfi
President & CEO
Alternaturals, Inc.
link to expected release day?
HIRU looks like just more scam artist at play. Weed symbol now gone off site and replaced with a frecking piñata http://hirucorp.com/
whacking out right before news ..lol
Alternaturals ?@Alternaturals 20m
Good Morning everyone. I hope you are all ready for an exciting week. Alternaturals is really getting ready to make a splash
Details
Alternaturals ?@Alternaturals 20m
Good Morning everyone. I hope you are all ready for an exciting week. Alternaturals is really getting ready to make a splash
Details
Early radar list AVOP AEGY FITX DBMM TTDZ ANAS
Early radar list AVOP AEGY FITX DBMM TTDZ ANAS
$DBMM .0007s getting smoked up !
$DBMM .0007s getting smoked up !
DBMM going parabolic
DBMM going parabolic
DBMM can go huge here
Whats smoking here besides the pps?
In DBMM
no idea . most shares are restircted or not in float so I could see that happening. It has to if they want to play big ball MMJ
Interesting thoughts on AVOP sterling
Couple things I am watching for to see if AVOP is going to become a major player.
1. Get the share structure down to e lower more appealing SS for investors.
2. Watching this website link for projects to be posted.
http://www.mjiginc.com/projects.html
As we seen with SLN* and what was $PMR* now ASA* ... share reduction news hits home well for investors. Would be huge here also.
AVOP now pink current http://www.otcmarkets.com/stock/AVOP/quote
HRRN top is blown off! Its all blue skies here. Best kind as they can make monster moves
HRRN top is blown off! Its all blue skies here. Best kind as they can make monster moves
HRRN top is blown off! Its all blue skies here. Best kind as they can make monster moves
HRRN hearing next MONA type move yeah count me in!
HRRN goign parabolic here! Huge loading .. news comign is the word
HRRN blue sky breakout chart http://stockcharts.com/h-sc/ui?s=HRRN&p=D&b=5&g=0&id=p66804023953&a=349284139
ready for .002s next
HRRN here she goes leaving trips next MONA in the making
HRRN here she goes leaving trips next MONA in the making